KEVEYIS can help patients gain greater control over Primary Periodic Paralysis (PPP). It’s proven to reduce the frequency, severity and duration of attacks.1,2
When compared with a placebo in a 9-week study1,2:
“I went from about one [attack] a week to one a month since starting KEVEYIS.”
Paul, KEVEYIS Patient and PPP Mentor
“I assumed my first call with my PAM was only for educational purposes, but after I talked to him, I realized how much better I was feeling emotionally, just being able to have contact with someone who understood what I was going through.”
Dennis, KEVEYIS patient and PPP Mentor
Hear from patients who gained greater control over PPP.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Concomitant Use of Aspirin or Other Salicylates
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.
The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.
Please see Full Prescribing Information.
Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.